Novo Nordisk NYSE: NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
Name | Novo Nordisk |
Ticker | NVO |
Exchange | NYSE |
Sector | Health Care |
Industry | Diabetes |
Price | 72.83 |
52W Low/High | 49.46 / 73.80 |
Market cap | 172 B |
1Y Total Return |
21.37%
Above Average |
1Y Volatility |
31.40%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
Details
Ticker | NVO |
Name | Novo Nordisk |
ISIN | US6701002056 |
CUSIP | |
Exchange | NYSE |
Sector | Health Care |
Industry | Diabetes |
Country | Denmark |
Currency | U.S. Dollar |
Share as of 1/22/21
Close Price | 72.83 |
52W Low/High | 49.46 / 73.80 |
Market cap | 172 B |
1Y Total Return |
21.37%
Above Average |
1Y Volatility |
31.40%
Low Risk |
Beta | 0.41 |
PE (trailing) |
25.48
Average |
12M Dividends | 0.203906 |
Last Dividend Date | 8/14/20 |
Dividend Yield | 0.28% |
Fin. Strength
Net Profit Margin | 34.4% |
Cash from Op. / Cur. Liabilities | 0.87 |
Diluted Earnings / Share | 2.86 |
ROE | 78.6% |
ROIC | 103.3% |
Price / Revenue | - |
Price / Book | - |
Price / CF | - |
Current Ratio | 1.0 |
Cur.Liabilities / Tot.Liabilities | 0.9 |
Financial Leverage | 0.07 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
19,545
|
17,549
|
17,202
|
17,980
|
16,831
|
15,468
|
|
Gross Profit |
16,359
|
14,710
|
14,442
|
15,147
|
14,274
|
13,143
|
|
R&D |
2,278
|
2,115
|
2,226
|
2,302
|
2,140
|
2,006
|
|
EBITDA |
9,624
|
8,427
|
8,130
|
8,662
|
7,814
|
7,354
|
|
Operating Income |
8,729
|
7,558
|
7,268
|
7,957
|
6,966
|
7,211
|
|
Net Income exc. Extra |
6,721
|
5,696
|
5,998
|
6,123
|
5,679
|
4,945
|
|
per Share | |||||||
Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
EPS exc. Extra |
2.86
|
2.38
|
2.46
|
2.46
|
2.23
|
1.91
|
|
Dividend |
0.20
|
0.15
|
0.16
|
0.18
|
0.21
|
0.08
|
|
Div. Yield (an.) |
1.88%
|
1.96%
|
2.22%
|
2.38%
|
3.39%
|
1.02%
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
21,867
|
18,369
|
15,921
|
15,538
|
13,233
|
12,716
|
|
Cash, Eq & Invt ShortTerm |
3,981
|
2,758
|
2,563
|
3,038
|
2,512
|
2,613
|
|
Total Current Assets |
11,510
|
9,324
|
8,459
|
9,063
|
7,815
|
7,685
|
|
Total Non-Current Assets |
10,356
|
9,045
|
7,463
|
6,476
|
5,419
|
5,031
|
|
Intangibles |
1,471
|
740
|
720
|
415
|
432
|
219
|
|
Total Liabilities |
12,558
|
10,582
|
8,497
|
8,087
|
6,972
|
6,281
|
|
Total Current Liabilities |
11,086
|
9,278
|
7,723
|
7,163
|
6,302
|
5,750
|
|
Long Term Debt |
1,473
|
1,304
|
775
|
923
|
670
|
532
|
|
Shareholder equity |
9,308
|
7,787
|
7,424
|
7,452
|
6,262
|
6,434
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
9,636
|
7,210
|
6,756
|
7,347
|
7,164
|
5,294
|
|
Depreciation |
849
|
868
|
498
|
539
|
468
|
429
|
|
Cash from Investing |
-1,963
|
-1,823
|
-1,741
|
-974
|
-1,326
|
-445
|
|
Capex |
1,086
|
1,438
|
1,467
|
1,206
|
1,021
|
677
|
|
Cash from Financing |
-7,095
|
-5,064
|
-5,464
|
-5,584
|
-5,945
|
-4,407
|
|
Stock Issued |
-2,210
|
-2,154
|
-2,488
|
-2,593
|
-2,335
|
-2,481
|
|
Debt (LT) Issued |
-145
|
-55
|
0
|
0
|
0
|
0
|
|
Free Cash Flow |
6,456
|
6,490
|
6,017
|
5,373
|
5,017
|
-
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
34.4%
|
32.5%
|
34.9%
|
34.1%
|
33.7%
|
32.0%
|
|
NCFO / Op.Income |
110.4%
|
95.4%
|
93.0%
|
92.3%
|
102.8%
|
73.4%
|
|
Current Ratio |
1.0
|
1.0
|
1.1
|
1.3
|
1.2
|
1.3
|
|
Financial Leverage D/E |
0.07
|
0.08
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Return on Capital Avg |
103.3%
|
103.7%
|
112.8%
|
123.8%
|
119.5%
|
237.4%
|
|
Return on Shareholder Equity |
78.6%
|
74.9%
|
80.6%
|
89.3%
|
89.5%
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available